Coverage of FDA decisions, advisory committees, submissions, guidances, policy changes, and global regulatory developments shaping the health science industry.
How Upcoming Tariffs Could Reshape Drug Pricing, Global Manufacturing, and Supply Chains President Trump’s latest threat to impose tariffs reaching 250% on pharmaceutical imports represents
Quick Summary •Market Reaction: Biotech stocks saw modest gains following Trump’s 2024 election victory, reflecting optimism about regulatory leniency and M&A activity. •Key Appointments: Speculation
Quick Summary Election Outcome: Donald Trump’s recent victory is anticipated to bring major changes to U.S. healthcare and biotech regulation. Key Players: Trump has suggested
Quick Summary Election Outcome: The 2024 election could reshape U.S. biotech regulation, with different regulatory priorities depending on the administration. Kamala Harris’s Approach: Harris focuses
Novartis’ €2.7 Billion Investment in MorphoSys Hits Setback as Safety Signal Delays Key Drug Filing Novartis’ recent acquisition of MorphoSys aimed to bring promising therapies
The healthcare landscape in 2024 is poised for significant advancements as key medical devices and therapies await FDA approval. These anticipated approvals hold the potential
